Vista Pharmaceuticals

Hyderabad, India Founded: 1992 • Age: 34 yrs Listed
Manufacturer of OTCs and generic prescription products

About Vista Pharmaceuticals

Vista Pharmaceuticals is a publicly listed company based in Hyderabad (India) founded in 1992. Manufacturer of OTCs and generic prescription products. Its Indian entity Vista Pharmaceuticals Ltd. reported revenue of β‚Ή5.72 Cr. Vista Pharmaceuticals offers products and services including Generic Drugs and Research and Development Services. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.

Company details

Vista Pharmaceuticals was founded in 1992 in Hyderabad, India, within the pharmaceuticals sector. Generic prescription and over-the-counter products are produced, including tablets, capsules, and liquids across multiple therapeutic categories. Operations focus on expanding the ANDA portfolio in the USA, developing generics for international markets, and delivering contract manufacturing services to other pharmaceutical firms.

  • Headquarters Hyderabad, India
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website vistapharmaceuticals.com
  • Social LinkedIn
  • Legal Name Vista Pharmaceuticals Ltd.
Key Metrics
  • Market Cap
    ₹38.35 Cr

    VISTAPH · BSE

  • Share Price
    ₹6.43

    +3.21% today

  • Revenue
    ₹5.40 Cr

    FY 2025-26 · -46.4% YoY

  • EBITDA
    −₹14.62 Cr

    Margin -270.7%

  • Net Profit
    −₹12.06 Cr

    FY 2025-26 · -158.8% YoY

Products & Services of Vista Pharmaceuticals

Vista Pharmaceuticals offers a comprehensive portfolio of products and services, including Generic Drugs and Research and Development Services.

Generic Drugs
Pharmaceutical Products

Generic drugs such as tablets, capsules, and liquids are formulated and distributed for various therapeutic categories.

Research and Development Services
R&D Services

Research and development activities are conducted for the formulation and registration of pharmaceutical products.

Board of directors of Vista Pharmaceuticals Ltd. (Vista Pharmaceuticals)

Vista Pharmaceuticals Ltd. is the primary company behind Vista Pharmaceuticals. The board of Vista Pharmaceuticals Ltd. currently have 9 directors; the longest-serving is Mallem Hanumantha Rao, appointed in 1993. 9 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Mallem Hanumantha Rao
DIN 00129311
Director16 Sep 199333 yrs 2 moVista Pharmaceuticals Ltd.
Dhananjaya Alli
DIN 00610909
Whole-time director07 Sep 201511 yrs 2 moVista Pharmaceuticals Ltd.
Stanley Prabhakar Reddy
DIN 07614532
Director12 Aug 201610 yrs 3 moVista Pharmaceuticals Ltd.
Umesh Virupakah Banakar
DIN 08074091
Director24 Feb 20188 yrs 8 moVista Pharmaceuticals Ltd.
Divya Bhavani Chakravarthula
DIN 08074187
Director24 Feb 20188 yrs 8 moVista Pharmaceuticals Ltd.
Divakar Reddy Yerrabommanahalli
DIN 08574891
Director30 Sep 20197 yrs 1 moVista Pharmaceuticals Ltd.
Umakanth Katta
DIN 07438554
Director13 Jul 20206 yrs 4 moVista Pharmaceuticals Ltd.
Pavan Sathvik Gilaka
DIN 09733182
Whole-time director14 Oct 20224 yrs 1 moVista Pharmaceuticals Ltd.
Murali Meraga
DIN 02537507
Managing Director14 Oct 20224 yrs 1 moVista Pharmaceuticals Ltd.

IPO & Listings of Vista Pharmaceuticals

Vista Pharmaceuticals is a publicly listed company on the BSE with ticker symbol VISTAPH in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date11 Jan 2002
  • Listed onBSE: 524711
  • Listed entityVista Pharmaceuticals Ltd.
  • Exchange sectorHealth technology
  • ISININE427C01021
  • Share price₹6.11 (+0.33% on the day) · 2026-10-14
  • Market capitalisation₹37.5 Cr
  • EPS (diluted, trailing year)₹-1.87
  • Volume (last session)5,855

Financials of Vista Pharmaceuticals

Exchange-reported figures of Vista Pharmaceuticals Ltd., the listed company behind Vista Pharmaceuticals (BSE: VISTAPH).

Financial Highlights

FY 2025-26 Β· Standalone
Revenue
₹5.40 Cr
-46.4% YoY
EBITDA
−₹14.62 Cr
-262.8% YoY
Profit After Tax
−₹12.06 Cr
-158.8% YoY
Net Worth
-
Total Assets
-
Total Debt
-

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue5.4010.0710.291.000.391.2722.76
Revenue growth-46.4%-2.1%+929.0%+156.4%-69.3%-94.4%-
EBITDA(14.62)(4.03)(3.55)(4.32)(1.28)(1.73)(4.80)
EBITDA margin-270.7%-40.0%-34.5%-432.0%-328.2%-136.2%-21.1%
Profit before tax(16.15)(5.30)(5.18)(5.88)(2.63)(3.81)(3.94)
Net profit(12.06)(4.66)(4.25)(5.67)(0.90)(2.01)(3.68)
Net profit margin-223.3%-46.3%-41.3%-567.0%-230.8%-158.3%-16.2%
EPS (β‚Ή)(1.96)(0.76)(0.96)(1.51)(0.24)(0.55)(1.21)
Balance sheet
Total assets-52.9548.5246.7348.0843.6345.16
Net worth-45.4240.4636.7135.4532.8529.64
Total debt-7.407.969.9612.5510.7115.47
Cash & bank-0.730.090.200.070.140.23
Net working capital-17.5513.9314.4416.048.0115.22
Cash flow
Cash from operations-(6.98)(4.91)(1.71)(0.99)(6.75)0.80
Cash from investing-(0.44)(0.79)(1.27)(0.01)(0.30)(1.73)
Cash from financing-8.065.593.110.946.960.28
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue0.000.002.421.461.523.232.562.49
Revenue growth (YoY)-100.0%-100.0%-5.5%-41.4%-15.6%---
Other income0.040.030.090.190.000.240.120.01
Total expenses0.847.065.424.902.634.144.073.32
EBITDA(0.84)(7.06)(3.00)(3.44)(1.11)(0.91)(1.51)(0.83)
EBITDA margin---124.0%-235.6%-73.0%-28.2%-59.0%-33.3%
Depreciation0.190.190.190.200.180.180.190.18
Interest0.340.550.180.180.190.210.220.25
Profit before tax(1.33)(7.77)(3.28)(3.63)(1.48)(1.06)(1.80)(1.25)
Tax(0.34)(1.91)(0.96)(1.03)(0.19)0.43(0.48)(0.28)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 17 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue0.000.002.421.461.523.232.562.49
Revenue growth (YoY)-100.0%-100.0%-5.5%-41.4%-15.6%---
Other income0.040.030.090.190.000.240.120.01
Total expenses0.847.065.424.902.634.144.073.32
EBITDA(0.84)(7.06)(3.00)(3.44)(1.11)(0.91)(1.51)(0.83)
EBITDA margin---124.0%-235.6%-73.0%-28.2%-59.0%-33.3%
Depreciation0.190.190.190.200.180.180.190.18
Interest0.340.550.180.180.190.210.220.25
Profit before tax(1.33)(7.77)(3.28)(3.63)(1.48)(1.06)(1.80)(1.25)
Tax(0.34)(1.91)(0.96)(1.03)(0.19)0.43(0.48)(0.28)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue5.4010.0710.291.000.391.2722.76
Revenue growth-46.4%-2.1%+929.0%+156.4%-69.3%-94.4%-
Other income0.320.440.330.400.170.203.75
Total expenses20.0214.1013.845.321.673.0027.56
Employee cost0.002.001.790.510.571.151.31
EBITDA(14.62)(4.03)(3.55)(4.32)(1.28)(1.73)(4.80)
EBITDA margin-270.7%-40.0%-34.5%-432.0%-328.2%-136.2%-21.1%
Depreciation0.750.740.720.620.620.731.35
Interest1.100.971.241.340.901.551.54
Profit before tax(16.15)(5.30)(5.18)(5.88)(2.63)(3.81)(3.94)
Tax(4.09)(0.64)(0.67)(0.21)(1.73)(1.80)(0.26)
Net profit(12.06)(4.66)(4.25)(5.67)(0.90)(2.01)(3.68)
Net profit margin-223.3%-46.3%-41.3%-567.0%-230.8%-158.3%-16.2%
EPS (β‚Ή)(1.96)(0.76)(0.96)(1.51)(0.24)(0.55)(1.21)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital-12.319.437.517.367.366.07
Reserves & surplus-33.1026.2223.0428.0925.4923.57
Shareholders' funds (net worth)-45.4240.4636.7135.4532.8529.64
Secured loans-7.407.969.9612.5511.2615.47
Unsecured loans-0.000.000.000.00(0.55)0.00
Total debt-7.407.969.9612.5510.7115.47
Total liabilities-52.9548.5246.7348.0843.6345.16
Assets
Gross block-27.1827.0626.7625.7425.7225.72
Net block-18.7019.3219.7419.3319.9320.66
Capital work in progress-10.149.829.339.089.088.78
Investments-0.050.020.020.030.040.02
Inventories-8.226.797.689.339.689.68
Sundry debtors-13.5414.2811.2510.462.1710.28
Cash & bank balances-0.730.090.200.070.140.23
Loans & advances-2.412.234.623.703.251.00
Total current assets-24.9023.3923.7523.5615.2421.19
Total current liabilities-7.359.469.317.527.235.97
Net working capital-17.5513.9314.4416.048.0115.22
Total assets-52.9548.5246.7348.0843.6345.16
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash-0.090.200.070.140.230.87
Net cash from operating activities-(6.98)(4.91)(1.71)(0.99)(6.75)0.80
Net cash from investing activities-(0.44)(0.79)(1.27)(0.01)(0.30)(1.73)
Net cash from financing activities-8.065.593.110.946.960.28
Net change in cash-0.64(0.11)0.13(0.07)(0.09)(0.64)
Closing cash-0.730.090.200.070.140.23
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-46.4%-2.1%+929.0%+156.4%-69.3%-94.4%-
EBITDA growth-262.8%-13.5%+17.8%-237.5%+26.0%+64.0%-
PBT growth-204.7%-2.3%+11.9%-123.6%+31.0%+3.3%-
Net income growth-158.8%-9.7%+25.0%-530.0%+55.2%+45.4%-
Revenue CAGR (3Y)+75.4%+195.6%+100.9%-64.7%-76.8%-64.7%-2.0%
EBITDA CAGR (3Y)+50.1%+46.6%+27.1%-3.5%---
Profitability & leverage
Net income margin-223.3%-46.3%-43.8%-567.0%-230.8%-158.3%-16.2%
Return on capital employed-0.0%0.0%0.0%0.0%0.0%-5.2%
Return on net worth-0.0%0.0%0.0%0.0%0.0%-11.3%
Debt / equity-0.180.230.310.340.420.41
Long-term debt / equity-0.060.110.170.240.240.18
Interest cover-7.16-20.34-29.04-27.13-47.37-63.01-25.04
Efficiency & per share
Fixed asset turnover-0.370.380.040.020.050.91
Inventory turnover-1.341.420.120.040.132.17
Debtors turnover-0.720.810.090.060.202.44
EPS (β‚Ή)(1.96)(0.76)(0.96)(1.51)(0.24)(0.55)(1.21)
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)0.007.387.568.139.648.939.76

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Vista Pharmaceuticals (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 72.52 M1,115
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Vista Pharmaceuticals

Premium access

Complete news archive for Vista Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vista Pharmaceuticals

Vista Pharmaceuticals was founded in 1992.

Vista Pharmaceuticals is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

The primary company behind Vista Pharmaceuticals, Vista Pharmaceuticals Ltd., reported revenue of β‚Ή5.72 Cr for FY 2026, down 46% year on year.

Vista Pharmaceuticals was founded in 1992 in Hyderabad, India, within the pharmaceuticals sector. Generic prescription and over-the-counter products are produced, including tablets, capsules, and liquids across multiple therapeutic categories. Operations focus on expanding the ANDA portfolio in the USA, developing generics for international markets, and delivering contract manufacturing services to other pharmaceutical firms.

Vista Pharmaceuticals offers Generic Drugs and Research and Development Services.

Yes, Vista Pharmaceuticals is publicly traded on BSE under the ticker symbol VISTAPH.

Vista Pharmaceuticals operates through Vista Pharmaceuticals Ltd..

The legal entities of Vista Pharmaceuticals currently have 11 directors, including Umakanth Katta, Suneel Pachipala, Pavan Sathvik Gilaka and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available